THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Clinical trials for THERAPY-RELATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for THERAPY-RELATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo combo aims to keep leukemia from returning after transplant
Disease control OngoingThis study tests whether giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant can help prevent leukemia or myelodysplasia from coming back. The trial includes 72 adults whose cancer is in remission or who have high-risk myelodysplastic syn…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 07:53 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers (like leukemia) who need a stem cell transplant. Orca-T is made from a donor's cells and includes special immune cells to help prevent a serious side effect called graft-versus-host disease (GVH…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
New combo therapy shows promise for Treatment-Linked blood cancer
Disease control OngoingThis study tests whether combining two drugs, venetoclax and azacitidine, can help people with a type of blood cancer called therapy-related myelodysplastic syndrome (t-MDS), which develops after prior cancer treatment. About 33 adults with intermediate to very high risk t-MDS wi…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo offers hope for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to prior therapy. The goal is to find the best dose and see how well the c…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC